State kicking MDwise from Indiana Medicaid program
Indianapolis-based MDwise, which said it has provided Indiana Medicaid services for more than 30 years, has already launched a court challenge to the state’s action.
Health Care & Insurance
Articles
UPDATE: Eli Lilly stock reaches new high, tops $1,000-per-share mark
Lilly’s shares have taken off in the wake of several significant deals and after it received fast-track regulatory review for highly anticipated weight-loss pill orforglipron.
Health care premium spikes set to squeeze small businesses
Premiums for Affordable Care Act plans, which are used for thousands of small businesses, are expected to jump 114% on average in the new year, when COVID-era tax credits expire.
Terre Haute hospital merger to move forward after COPA approval
The Certificate of Public Advantage, or COPA, allows hospital mergers that the Federal Trade Commission otherwise considers illegal because they reduce competition and often create monopolies.
Trump unveils deal with Lilly, Novo to expand coverage, lower costs on obesity drugs
Thursday’s announcement is the latest attempt by the Trump administration to rein in soaring drug prices in its efforts to address cost-of-living concerns among voters.
Lilly earnings soar on growth of Mounjaro, Zepbound
With quarterly revenue up 54% from a year ago, Eli Lilly raised it guidance for the year, with the company now expecting revenue in the range of $63 billion to $63.5 billion.
Health insurance sticker shock begins as shutdown battle over subsidies rages
Lawmakers face greater pressure to act as Americans who buy insurance through the Affordable Care Act are seeing, or about to see, the consequences of enhanced subsidies expiring at the end of the year.
Novo, Lilly shares fall as Trump touts ‘much lower’ Ozempic price
Mehmet Oz, head of the Centers for Medicare and Medicaid Services, said talks over the price of weight-loss drugs are still ongoing.
Dr. Richard Feldman: Biden dropped ball on menthol, so Trump should push on
Menthol cigarettes have been aggressively marketed to African Americans, creating a significant disparity in use.
CDC recommends coronavirus vaccine with new caveat. Here’s what to know.
The Centers for Disease Control and Prevention on Monday said it had officially recommended updated COVID vaccines, creating a new system to get a shot that’s slightly more complicated than in previous years.
Drug made from marijuana reduced back pain in large study
The 800-patient study by a German drugmaker is the latest evidence of the therapeutic properties of cannabis, which remains illegal under U.S. federal law even as most states have made it available for medical or recreational use.
Government shutdown draws closer as congressional leaders head to the White House
White House aides, ahead of the meeting, made it clear the Republican administration had no intention to negotiate.
What new tariffs mean for pharmaceuticals, patented drugs
President Donald Trump’s announcement that his administration will impose a 100 percent tariff on patented pharmaceutical products sparked confusion Friday, as government officials, drug companies and trade groups sought clarity on how the levy would be applied.
Indiana interim courts committee concludes without recommendations
After meeting for just over three cumulative hours this year, the interim courts committee came to a close Tuesday without making any recommendations on its assigned topic: medical debt.
CVS Health subsidiary Omnicare files for bankruptcy protection
The filing comes two months after the long-term care business was ordered to pay $949 million when a federal court found it liable for filing fraudulent claims for some prescription drugs.
Pfizer amps up push into obesity treatments with $4.9B deal for Metsera
Demand for obesity treatments has soared recently, due to unprecedented weight loss provided by regular injections of market leaders Wegovy from Novo Nordisk and Zepbound from Indianapolis-based Eli Lilly and Co.
Weight-loss drugs can cut future health costs. The fight is over who pays now.
Evidence from clinical trials shows that GLP-1s have benefits beyond weight loss, preventing related chronic conditions and ultimately blunting health-plan costs. But the savings might take decades, experts say.
Medicaid work requirements delayed until 2027 following federal action
Other parts of Indiana’s HIP 3.0 proposal are still under consideration, including an expansion on provider taxes, cost-sharing requirements and wellness incentives.
New bill seeks to restore millions in Medicaid funding to Indiana hospitals
Hospital leaders who spoke with Inside INdiana Business emphasized the bill wouldn’t increase funding, it would give hospitals access to funding that’s already been allocated.
Health insurance premiums poised to spike over drug costs, tariff threats
In explaining the rising prices, insurers and employers point to two recent factors: the tariffs on pharmaceutical imports and the high cost of new obesity treatments.